ClinicalTrials.gg
CompletedNCT00937404Updated Dec 17, 2018Results posted

Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants

A Phase 1 interventional study of Poliorix in Poliomyelitis, sponsored by GlaxoSmithKline. Completed at 1 site in China. Open to participants aged 60 Days to 90 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-17.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
60 Days to 90 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis — 3 open to participants now, 3 under way, none of them phase 3. Poliovirus Vaccine, Inactivated · Poliomyelitis.

Enrollment
17th of 18
25 · median 672
Started
2009
with 1 other
Phase 1
2 of 18
none open now
Registered
1st of 18
by date
Lead sponsor
2 of 18
GlaxoSmithKline

Among the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis, this one is the 17th largest by enrollment, is one of 2 that started in 2009, is one of 2 in phase 1, and was the 1st registered.

Poliomyelitis

275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.

Browse Poliomyelitis studies →

Open to participants now

3 of the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Poliovirus Vaccine, Inactivated

Poliovirus Vaccine, Inactivated: first FDA approval 2002 (Pediarix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 60 Days to 90 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis, or all of them as a file.
02

Study summary

The study will evaluate the safety and reactogenicity of Poliorix given as primary vaccination course to Chinese children at 2, 3 and 4 months of age.

03

Conditions studied

  • Poliomyelitis

Browse trials for

Keywords

  • IPV
04

Who can participate

Ages eligible
60 Days to 90 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A male or female infant between, and including, 60 and 90 days of age at the time of the first vaccination.
  • Born after a gestation period of 36 to 42 weeks inclusive.
  • Subjects who the investigator believes that their parents/ guardians can and will comply with the requirements of the protocol should be enrolled in the study.
  • Written obtained from the parent or guardian of the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration of or other immune-modifying drugs since birth.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
  • Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period, with exception of DTP, Hib and/or vaccine(s).
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Evidence of previous or intercurrent poliomyelitis disease or vaccination.
  • History of seizures or progressive neurological disease.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s).
  • Major congenital defects or serious chronic illness. The following condition is temporary or self-limiting and a subject may be vaccinated once the condition has resolved and no other exclusion criteria are met:
  • Current febrile illness or axillary temperature > 37.0 ºC or other moderate to severe illness within 24 hours of study vaccine administration.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    IPV Group

    Healthy male or female subjects between, and including, 60 and 90 days of age at the time of the first vaccination, receive 3 doses of Poliorix at 2 (Study Day 0, Visit 1), 3 (Study Month 1, Visit 2) and 4 (Study Month 2, Visit 3) months of age, administered intramuscularly into the upper right side of the thigh.

    Biological: Poliorix

Interventions

  • BiologicalPoliorix

    All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.

06

What researchers measure

Primary outcomes

  1. Number of Subjects Reporting Solicited Local Symptoms

    Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of the symptom irrespective of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimetres (mm) of injection site.

    Time frame: During the 4-day follow-up period after each dose of study vaccine.

  2. Number of Subjects Reporting Solicited General Symptoms

    Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever \[defined as axillary temperature equal to or above (≥) 37.1 degrees Celsius (°C)\]. Any = occurrence of symptom regardless of intensity grade of relationship to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = subject did not eat at all. Grade 3 fever = fever above (\>) 39.0°C. Related = symptom assessed by the investigator as related to vaccination.

    Time frame: During the 4-day follow-up period after each dose of study vaccine.

  3. Number of Subjects Reporting Unsolicited Adverse Events (AEs)

    Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.

    Time frame: During the 31-days follow-up period after each dose of the study vaccine.

  4. Number of Subjects Reporting Serious Adverse Events (SAEs)

    SAEs assessed included any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject.

    Time frame: During the entire study period (from Dose 1 up to one month following last vaccine dose).

07

Results

Posted Dec 17, 2018

Participant flow

Participant flow — Overall Study
MilestoneIPV Group
Started25
Completed23
Not completed2
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Subjects Reporting Solicited Local Symptoms

Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of the symptom irrespective of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimetres (mm) of injection site.

Time frame:
During the 4-day follow-up period after each dose of study vaccine.
Reported as:
Count of participants · Participants
Number of Subjects Reporting Solicited Local Symptoms
ParticipantsIPV Group
Any Pain, Dose 11
Grade 3 Pain, Dose 10
Any Redness, Dose 12
Grade 3 Redness, Dose 10
Any Swelling, Dose 11
Grade 3 Swelling, Dose 10
Any Pain, Dose 22
Grade 3 Pain, Dose 20
Any Redness, Dose 21
Grade 3 Redness, Dose 20
Any Swelling, Dose 21
Grade 3 Swelling, Dose 20
Any Pain, Dose 31
Grade 3 Pain, Dose 30
Any Redness, Dose 30
Grade 3 Redness, Dose 30
Any Swelling, Dose 30
Grade 3 Swelling, Dose 30
Any Pain, Across doses3
Grade 3 Pain, Across doses0
Any Redness, Across doses2
Grade 3 Redness, Across doses0
Any Swelling, Across doses2
Grade 3 Swelling, Across doses0
PrimaryNumber of Subjects Reporting Solicited General Symptoms

Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever \[defined as axillary temperature equal to or above (≥) 37.1 degrees Celsius (°C)\]. Any = occurrence of symptom regardless of intensity grade of relationship to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = subject did not eat at all. Grade 3 fever = fever above (\>) 39.0°C. Related = symptom assessed by the investigator as related to vaccination.

Time frame:
During the 4-day follow-up period after each dose of study vaccine.
Reported as:
Count of participants · Participants
Number of Subjects Reporting Solicited General Symptoms
ParticipantsIPV Group
Any Drowsiness, Dose 17
Grade 3 Drowsiness, Dose 10
Related Drowsiness, Dose 17
Any Irritability, Dose 110
Grade 3 Irritability, Dose 10
Related Irritability, Dose 110
Any Loss of appetite, Dose 17
Grade 3 Loss of appetite, Dose 10
Related Loss of appetite, Dose 17
Any Fever, Dose 18
Grade 3 Fever, Dose 10
Related Fever, Dose 16
Any Drowsiness, Dose 22
Grade 3 Drowsiness, Dose 20
Related Drowsiness, Dose 22
Any Irritability, Dose 27
Grade 3 Irritability, Dose 20
Related Irritability, Dose 26
Any Loss of appetite, Dose 24
Grade 3 Loss of appetite, Dose 20
Related Loss of appetite, Dose 23
Any Fever, Dose 23
Grade 3 Fever, Dose 20
Related Fever, Dose 23
Any Drowsiness, Dose 33
Grade 3 Drowsiness, Dose 30
Related Drowsiness, Dose 31
Any Irritability, Dose 37
Grade 3 Irritability, Dose 32
Related Irritability, Dose 33
Any Loss of appetite, Dose 36
Grade 3 Loss of appetite, Dose 30
Related Loss of appetite, Dose 33
Any Fever, Dose 34
Grade 3 Fever, Dose 30
Related Fever, Dose 32
Any Drowsiness, Across doses8
Grade 3 Drowsiness, Across doses0
Related Drowsiness, Across doses8
Any Irritability, Across doses14
Grade 3 Irritability, Across doses2
Related Irritability, Across doses12
Any Loss of appetite, Across doses9
Grade 3 Loss of appetite, Across doses0
Related Loss of appetite, Across doses8
Any Fever, Across doses12
Grade 3 Fever, Across doses0
Related Fever, Across doses9
PrimaryNumber of Subjects Reporting Unsolicited Adverse Events (AEs)

Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.

Time frame:
During the 31-days follow-up period after each dose of the study vaccine.
Reported as:
Count of participants · Participants
Number of Subjects Reporting Unsolicited Adverse Events (AEs)
ParticipantsIPV Group
Number of Subjects Reporting Unsolicited Adverse Events (AEs)15
PrimaryNumber of Subjects Reporting Serious Adverse Events (SAEs)

SAEs assessed included any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject.

Time frame:
During the entire study period (from Dose 1 up to one month following last vaccine dose).
Reported as:
Count of participants · Participants
Number of Subjects Reporting Serious Adverse Events (SAEs)
ParticipantsIPV Group
Number of Subjects Reporting Serious Adverse Events (SAEs)0

Adverse events

Collected over Solicited symptoms: during the 4-day post-vaccination period after each vaccine dose. Unsolicited AEs: during the 31-day post-vaccination period after each vaccine dose. SAEs: during the entire study period (from Dose 1 up to one month following last vaccine dose).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IPV Group0/25 (0%)0/25 (0%)20/25 (80%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventIPV Group
PyrexiaGeneral disorders16/25
IrritabilityPsychiatric disorders14/25
Decreased appetiteMetabolism and nutrition disorders9/25
SomnolenceNervous system disorders8/25
Upper respiratory tract infectionInfections and infestations7/25
DiarrhoeaGastrointestinal disorders5/25
NasopharyngitisInfections and infestations4/25
DyspepsiaGastrointestinal disorders3/25
PainGeneral disorders3/25
ErythemaSkin and subcutaneous tissue disorders2/25

Baseline characteristics

Age, Continuous
Age, Continuous(Weeks)IPV Group
Mean9.6 ± 1.38
Sex: Female, Male
Sex: Female, Male(Participants)IPV Group
Female15
Male10
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)IPV Group
Asian-Chinese Heritage25
08

Study locations

1 site
  • GSK Investigational Site
    Wuzhou, Guangxi, China
09

References and documents

Publications

  • Li R, Li CG, Li Y, Liu Y, Zhao H, Chen X, Kuriyakose S, Van Der Meeren O, Hardt K, Hezareh M, Roy-Ghanta S. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China. Vaccine. 2016 Mar 14;34(12):1436-43. doi: 10.1016/j.vaccine.2016.02.010. Epub 2016 Feb 9. PubMed 26873055 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2009 to primary completion in Nov 2009, 3 months.

Results were first posted in Dec 2018, 9 years 1 month after primary completion.

Of 12 phase 1 interventional studies under Poliomyelitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 3 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2009
First posted
Jul 13, 2009
StartActual
Aug 4, 2009
Primary completionActual
Nov 13, 2009
CompletionActual
Nov 13, 2009
Results first posted
Dec 17, 2018
Last update
Dec 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00937404
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 13, 2009
Start date
Aug 4, 2009
Primary completion
Nov 13, 2009
Completion
Nov 13, 2009
Results posted
Dec 17, 2018
Last update
Dec 17, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Poliovirus Vaccine, Inactivated

Start the discussion